We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.11%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$709M
AUM Growth
+$195M
Cap. Flow
-$68.5M
Cap. Flow %
-9.65%
Top 10 Hldgs %
69.09%
Holding
206
New
48
Increased
50
Reduced
50
Closed
43

Top Buys

Rank Stock Value
1
ATER icon
Aterian
ATER
+$8.44M
2
COCP icon
Cocrystal Pharma
COCP
+$7.74M
3
RCON icon
Recon Technology
RCON
+$7.52M
4
LNAI
Lunai Bioworks
LNAI
+$5.46M
5
KRBP
Kiromic BioPharma, Inc. Common Stock
KRBP
+$4.18M

Top Sells

Rank Stock Value
1
VANI icon
Vivani Medical
VANI
+$4.81M
2
PENN icon
PENN Entertainment
PENN
+$4.24M
3
VTSI icon
VirTra
VTSI
+$3.45M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.42M
5
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 10.24%
2 Consumer Discretionary 1.47%
3 Technology 1.37%
4 Financials 1.09%
5 Consumer Staples 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HMCOW
126
DELISTED
HumanCo Acquisition Corp. Warrant
HMCOW
$238K 0.03%
200,314
+59,178
+42% +$70.1K
UK icon
127
Ucommune International Ltd Class A Ordinary Shares
UK
$1.32M
$223K 0.03%
42
-12
-22% -$66.8K
HEPA
128
CALL
DELISTED
Hepion Pharmaceuticals
HEPA
$220K 0.03%
+1
New +$1.83K
PALI icon
129
Palisade Bio
PALI
$351M
$214K 0.03%
+70
New +$318K
CSCI
130
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$214K 0.03%
2,442
-3,542
-59% -$337K
PLUR icon
131
PUT
Pluri
PLUR
$18.1M
$210K 0.03%
66
-151
-70% -$5K
NMAD
132
Nomad Power Solutions
NMAD
$81M
$199K 0.03%
6,551
-1,423
-18% -$40.9K
HEPA
133
PUT
DELISTED
Hepion Pharmaceuticals
HEPA
$194K 0.03%
1
– –
NOVN
134
DELISTED
Novan, Inc. Common Stock
NOVN
$192K 0.03%
+19,132
New +$225K
CTRM icon
135
PUT
Castor Maritime
CTRM
$18.3M
$189K 0.03%
+73
New +$2.97K
HCDIW
136
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIW
$171K 0.02%
+272,103
New +$191K
NBRV
137
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$165K 0.02%
49
+30
+158% +$1.12K
TVTX icon
138
Travere Therapeutics
TVTX
$5.2B
$147K 0.02%
+10,042
New +$198K
MMAT
139
PUT
DELISTED
Meta Materials Inc. Common Stock
MMAT
$136K 0.02%
+2
New +$1.12K
PHIO icon
140
Phio Pharmaceuticals
PHIO
$11.7M
$117K 0.02%
479
+266
+125% +$65.6K
RDHL
141
CALL
Redhill Biopharma
RDHL
$4.44M
– –
0
– –
NTBL
142
PUT
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$117K 0.02%
14
-10
-42% -$758
TRIL
143
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$117K 0.02%
121
-525
-81% -$4.94K
CRDF icon
144
PUT
Cardiff Oncology
CRDF
$63.6M
$111K 0.02%
167
-2
-1% -$17
POL
145
DELISTED
Polished.com Inc.
POL
$110K 0.02%
+572
New +$156K
LIXTW
146
DELISTED
Lixte Biotechnology Warrants
LIXTW
$107K 0.02%
140,089
-17,285
-11% -$12.3K
EVFM
147
PUT
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$107K 0.02%
+63
New +$1.19K
IO
148
CALL
DELISTED
ION Geophysical Corporation
IO
$105K 0.01%
+500
New +$1.07K
NMTR
149
CALL
DELISTED
9 Meters Biopharma
NMTR
$95K 0.01%
+43
New +$1.06K
CSCI
150
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$81K 0.01%
9
-11
-55% -$1.05K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sabby Management held 206 positions worth $709M, up 38% from $514M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $68.5M in Q2 2021, closing 43 positions and reducing 50 holdings. Its most notable exit was PENN Entertainment, an estimated $4.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Sabby Management opened a new position in Aterian worth $6.33M.

  • Sabby Management's largest Q2 2021 buy was Aterian: 36,083 shares worth $6.33M.
  • Sabby Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $2.87M increase.
  • Sabby Management's biggest Q2 2021 reduction was Vivani Medical, cutting an estimated $4.81M.
  • Sabby Management fully exited PENN Entertainment in Q2 2021, selling an estimated $4.24M.
  • Sabby Management's ten largest holdings make up 69% of its $709M portfolio in Q2 2021.
  • Sabby Management opened 48 new positions and closed 43 in Q2 2021.
  • Sabby Management's portfolio value rose 38% quarter-over-quarter to $709M.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.